This study was designed to assess the efficacy and safety of pregabalin-a novel alpha(2)-delta ligand with analgesic, anxiolytic, and anticonvulsant activity-for treating neuropathic pain in patients with post-herpetic neuralgia (PHN). Two hundred and thirty-eight patients were randomised into this multicentre, doubleblind, placebo-controlled trial to receive 150 (n=81), 300 mg/day (n=76) pregabalin, or placebo (n=81) for 8 weeks. Among the exclusion criteria was failure to respond to previous treatment for PHN with gabapentin at doses > or =1200 mg/day. Endpoint mean pain scores were significantly reduced in patients receiving 150 or 300 mg/day pregabalin compared with placebo. Efficacy was observed as early as week 1 and was maintained throughout the study. Significantly more patients in both pregabalin groups (150 mg, 26%; 300 mg, 28%) were responders (> or =50% decrease in mean pain score from baseline to endpoint) than in the placebo group (10%). Additionally, by week 1 and for the study's duration, 150 and 300 mg/day pregabalin significantly reduced weekly mean sleep interference scores. More pregabalin-treated patients than placebo-treated patients reported that they were 'much improved' or 'very much improved'. Health-related quality-of-life (HRQoL) measurements using the SF-36 Health Survey demonstrated improvement in the mental health domain for both pregabalin dosages, and bodily pain and vitality domains were improved in the 300 mg/day group. The most frequent adverse events were dizziness, somnolence, peripheral oedema, headache, and dry mouth. Pregabalin efficaciously treated the neuropathic pain of PHN. Additionally, pregabalin was associated with decreased sleep interference and significant improvements in HRQoL measures.

Background: This study assesses the validity and reliability of the Spanish version of DN4 questionnaire as a tool for differential diagnosis of pain syndromes associated to a neuropathic (NP) or somatic component (non-neuropathic pain, NNP).

No abstract

No abstract

Introduction: This open-label, phase 3b study

In this paper, we explore traffic analysis attacks on Tor that are conducted solely with middle relays rather than with relays from the entry or exit positions. We create a methodology to apply novel Tor circuit and website fingerprinting from middle relays to detect onion service usage; that is, we are able to identify websites with hidden network addresses by their traffic patterns. We also carry out the first privacypreserving popularity measurement of a single social networking website hosted as an onion service by deploying our novel circuit and website fingerprinting techniques in the wild. Our results show: (i) that the middle position enables wide-scale monitoring and measurement not possible from a comparable resource deployment in other relay positions, (ii) that traffic fingerprinting techniques are as effective from the middle relay position as prior works show from a guard relay, and (iii) that an adversary can use our fingerprinting methodology to discover the popularity of onion services, or as a filter to target specific nodes in the network, such as particular guard relays.

No abstract

Under standard care conditions, neuropathic and mixed pain are associated with impaired physical and mental QoL, producing a substantial level of disability in these patients.